Human IFNg / IL-2 Dual ELISpot Set
| Code | Size | Price |
|---|
| 874.040.015S | 15 x 96 (sterile plates) | £1,985.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Application: ELISpot
Further Information
Cross reaction:
Cross reactivity with simian IFN-g
Description:
Diaclone Dual ELISpot Sets include capture and detection antibodies for both of the targeted cytokines Streptavidin-Alkaline Phosphatase conjugated anti-FITC HRP conjugated mAb BSA BCIP/NTB and AEC blocking reagent.
Detection Target:
IFNg / IL-2
Incubation:
3h30 after cell stimulation
Reactivity:
Human
Research Area:
Cytokines / Growth Factors
Specificity:
Recognizes both natural and recombinant human IFN-g and IL-2
References
- Chauvat A. et al.Hum Vaccin Immunother.2014; 10(1): 104-13. Clinical validation of IFNgamma/IL-10 and IFNgamma/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans.. https://www.ncbi.nlm.nih.gov/pubmed/24084262
- De Haes W. et al.Mol Ther.2010; 18(7): 1408-16. Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses.. https://www.ncbi.nlm.nih.gov/pubmed/20461059
- Hagin D. et al. J Allergy Clin Immunol. 2021 Sep; 148(3): 739?749. . Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. https://pubmed.ncbi.nlm.nih.gov/34087242/
- Lori F. et al.PLoS One2012; 7(10): e47485. VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.. https://www.ncbi.nlm.nih.gov/pubmed/23094055
- Plana M. et al.Immunology2011; 133(3): 318-28. The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses.. https://www.ncbi.nlm.nih.gov/pubmed/21501161
- Ram R. et al. Transplant Cell Ther. 2021 Sep; 27(9): 788?794. . Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy?A Single-Center Prospective Cohort Study. https://pubmed.ncbi.nlm.nih.gov/34214738/